In Addition, Our Drug Actually Rocks

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

The press release touting Pfizer (NYSE: PFE  ) and Bristol-Myers Squibb's (NYSE: BMY  ) atrial fibrillation drug makes the whole thing sound like an afterthought: "In addition, Eliquis met the key secondary endpoints of superiority on efficacy and on ISTH (International Society on Thrombosis and Haemostasis) major bleeding compared to warfarin."

But those 26 words could be worth billions to Pfizer and Bristol-Myers Squibb. Yes, billions.

It's a three-horse race to replace warfarin: Eliquis, Boehringer Ingelheim's Pradaxa, and Xarelto from Bayer and Johnson & Johnson (NYSE: JNJ  ) . There's data that shows Pradaxa is superior to warfarin, but it wasn't a blinded study -- patients knew which drug they were getting -- so it's not considered all that strong. Xarelto failed to beat warfarin in atrial fibrillation patients.

Pfizer and Bristol-Myers hedged their bets making non-inferiority to warfarin the primary endpoint with superiority as the secondary endpoint, which is the reason the duo didn't lead with the more important news. Proving that Eliquis is as good as warfarin -- and its nasty side effect of major bleeding -- would have been good enough to get Eliquis on the market. Topping warfarin on efficacy and safety should be enough to rocket past Pradaxa and Xarelto.

The companies plan on submitting marketing applications for Eliquis in the U.S. and Europe later this year, which would make it the third drug to make it to market. Being third to the party with ho-hum data would result in ho-hum sales for sure. With superior data -- assuming they live up to the hype of the press release -- Pfizer and Bristol-Myers can expect major sales from Eliquis.

Looking for more stock ideas? Here are five stocks that The Motley Fool owns and its analysts think you should, too.

Fool contributor Brian Orelli holds no position in any company mentioned. See his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Pfizer and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (7)

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1511386, ~/Articles/ArticleHandler.aspx, 10/26/2016 4:05:56 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 6 hours ago Sponsored by:
DOW 18,169.27 -53.76 -0.30%
S&P 500 2,143.16 -8.17 -0.38%
NASD 5,283.40 -26.43 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/25/2016 4:00 PM
BMY $49.55 Up +0.32 +0.65%
Bristol-Myers Squi… CAPS Rating: ****
JNJ $113.96 Up +0.35 +0.31%
Johnson and Johnso… CAPS Rating: ****
PFE $32.28 Up +0.15 +0.47%
Pfizer CAPS Rating: ****